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A B S T R A C T
Background
Pregnant women with pre-existing diabetes (Type 1 or Type 2) have increased rates of adverse maternal and neonatal outcomes. Current
clinical guidelines support elective birth, at or near term, because of increased perinatal mortality during the third trimester of pregnancy.
This review replaces a review previously published in 2001 that included “diabetic pregnant women”, which has now been split into
two reviews. This current review focuses on pregnant women with pre-existing diabetes (Type 1 or Type 2) and a sister review focuses
on women with gestational diabetes.
Objectives
To assess the effect of planned birth (either by induction of labour or caesarean birth) at or near term gestation (37 to 40 weeks’
gestation) compared with an expectant approach, for improving health outcomes for pregnant women with pre-existing diabetes and
their infants. The primary outcomes relate to maternal and perinatal mortality and morbidity.
Search methods
We searched Cochrane Pregnancy and Childbirth’s Trials Register, ClinicalTrials.gov, the WHO International Clinical Trials Registry
Platform (ICTRP) (15 August 2017), and reference lists of retrieved studies.
Selection criteria
We planned to include randomised trials (including those using a cluster-randomised design) and non-randomised trials (e.g. quasi-
randomised trials using alternate allocation) which compared planned birth, at or near term, with an expectant approach for pregnant
women with pre-existing diabetes.
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Data collection and analysis
Two of the review authors independently assessed study eligibility. In future updates of this review, at least two of the review authors will
extract data and assess the risk of bias in included studies. We will also assess the quality of the evidence using the GRADE approach.
Main results
We identified no eligible published trials for inclusion in this review.
We did identify one randomised trial which examined whether expectant management reduced the incidence of caesarean birth in
uncomplicated pregnancies of women with gestational diabetes (requiring insulin) and with pre-existing diabetes. However, published
data from this trial does not differentiate between pre-existing and gestational diabetes, and therefore we excluded this trial.
Authors’ conclusions
In the absence of evidence, we are unable to reach any conclusions about the health outcomes associated with planned birth, at or near
term, compared with an expectant approach for pregnant women with pre-existing diabetes.
This review demonstrates the urgent need for high-quality trials evaluating the effectiveness of planned birth at or near term gestation
for pregnant women with pre-existing (Type 1 or Type 2) diabetes compared with an expectant approach.
P L A I N L A N G U A G E S U M M A R Y
Planned birth at or near term for improving health outcomes for pregnant women with pre-existing diabetes and their infants
What is the issue?
The aim of this Cochrane review was to find out if planning an elective birth at or near the term of pregnancy, compared to waiting for
labour to start spontaneously, has an impact on the health of women with diabetes and the health of their babies. This review focuses
on women who have diabetes before becoming pregnant (pre-existing diabetes). Elective birth is carried out either by induction of
labour or caesarean section, and ’at or near term’ means 37 to 40 weeks’ gestation.
To answer this question, we searched for all relevant studies (date of search: 15 August 2017), with the aim of collecting and analysing
them together.
Why is this important?
When women with diabetes (Type 1 or Type 2) become pregnant they are at higher risk of complications than women who do not
have diabetes. For example, their babies may be larger and have a higher risk of death in the later weeks of pregnancy. Because of these
risks, many clinicians have recommended that women with diabetes have an elective birth (usually by induction) at or near term (37 to
40 weeks’ gestation), rather than waiting for labour to start spontaneously or until 41 weeks’ gestation if all is well. Induction has the
disadvantage of increasing the incidence of forceps or ventouse births, and women often find it difficult to cope with an induced labour.
Caesarean section is a major operation which can lead to blood loss, infections and increased chance of problems with subsequence
births. Early birth can increase the chance of breathing problems for babies. It is important to know which approach to birth has a
better impact on the health outcomes of women with pre-existing diabetes and their babies.
What evidence did we find?
We found no studies that addressed our specific question.
What does this mean?
In the absence of randomised studies, we are unable to say if women with pre-existing diabetes and their babies experience better health
outcomes if they have a planned birth (by induction of labour or caesarean section at 37 to 40 weeks’ gestation) compared to waiting
for labour to begin spontaneously or until 41 weeks’ gestation if all is well. More research is needed to answer this question.
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B A C K G R O U N D
There are several clinical situations where planned birth has been
advocated with the aim of reducing adverse outcomes for both
mother and baby (Dodd 2014). These include: an otherwise low-
risk singleton pregnancy after 41 weeks (Gulmezoglu 2012); for
women with an uncomplicated twin pregnancy at 37 weeks’ ges-
tation (Dodd 2014); and for women at 37 to 40 weeks’ gestation
where a clinical suspicion of macrosomia exists (Boulvain 2016).
Systematic reviews of these three scenarios reveal that induction
of labour after 41 weeks is the only intervention associated with a
reduction in perinatal mortality (Gulmezoglu 2012). A previously
published Cochrane review concluded that elective birth at term
in pregnant women with insulin-requiring diabetes reduces the
risk of macrosomia but does not impact on maternal or neonatal
morbidity (Boulvain 2001).
The original review ’Elective delivery in diabetic pregnant women’
(Boulvain 2001) has nowbeen split into the following two reviews.
1. Planned birth at or near term for improving health
outcomes for pregnant women with pre-existing diabetes and
their infants (this review)
2. Planned birth at or near term for improving health
outcomes for pregnant women with gestational diabetes and
their infants (Biesty 2018)
As gestational diabetes is typically a transient glucose abnormality
occurring late in the second trimester of pregnancy, whilst pre-
existing diabetes exists throughout the entire pregnancy, it is im-
portant to clearly differentiate between these different conditions
when approaching the issue of planned birth. It is acknowledged
that there are similarities in the background, methods and out-
comes between these two systematic reviews.
Description of the condition
Pre-existing diabetes refers to maternal diabetes that existed prior
to the pregnancy. This typically refers to Type 1 and Type 2 dia-
betes, however the term also encompasses rarer forms of diabetes,
e.g. Maturity Onset Diabetes of the Young (MODY). Type 1 di-
abetes is characterised by autoimmune destruction of beta cells,
usually leading to absolute insulin deficiency; Type 2 diabetes oc-
curs due to a progressive loss of insulin secretion on a background
of insulin resistance, and is likely to be the result of interactions
between genetic, environmental and immunological factors (ADA
2016; Zaccardi 2016). Although estimates vary, it is believed that
0.5% to 0.9% of pregnancies are complicated by pre-existing di-
abetes (Correa 2015; NICE 2015). While the prevalence of both
Type 1 and Type 2 diabetes has increased in recent years (NICE
2015), the rate of Type 2 diabetes in pregnant women in the USA
more than quadrupled in the period from 1994 to 2004, overtak-
ing the rates of pre-existing Type 1 diabetes (Albrecht 2010). This
increase in prevalence of Type 2 diabetes is in line with the world-
wide rise in obesity rates and advancing maternal age (ACOG
2005; Egan 2015; Zhu 2016).
In the setting of pre-existing diabetes, pregnancy is considered to
be high risk and is associated with increased rates of adverse ma-
ternal and neonatal outcomes. Studies from the United Kingdom
and Ireland reveal a congenital malformation rate twice that of
the background population (24/1000), a five-fold increased risk
of stillbirth (25/1000), and a three-fold increased risk of perinatal
mortality and caesarean birth (25/1000) (Macintosh 2006;Dunne
2009; Egan 2015). During the third trimester, issues of signifi-
cant concern are: late fetal death; complications necessitating pre-
mature birth; and the potential for birth trauma associated with
fetal macrosomia (Cousins 1987; Hanson 1993; Dunne 2009).
Although recent research has noted a higher risk of adverse neona-
tal outcomes including stillbirths and congenital abnormalities in
offspring of women with Type 1 compared to Type 2 diabetes
(Owens 2015), an earlier systematic review found perinatal mor-
tality to be higher for women with Type 2 compared with Type
1 diabetes (Balsells 2009). It should be noted that women with
Type 2 diabetes are more commonly from ethnic minorities and
are often cared for in community settings with minimal access
to specialist care (Murphy 2010). This makes them an especially
vulnerable group.
The hyperglycaemia-hyperinsulinaemia hypothesis, also known as
the Pederson Hypothesis, aims to explain the underlying pathol-
ogy that leads to the disordered fetal growth associated with the di-
abetic pregnancy. It states that “maternal hyperglycaemia results in
fetal hyperglycaemia and, hence, in hypertrophy of fetal islet tissue
with insulin-hypersecretion. This again means a greater fetal utili-
sation of glucose” (Pedersen 1952; Pedersen 1967). More recently,
it has been suggested that additional factors such as alterations in
lipid metabolism and inflammatory change may contribute to the
abnormal metabolic environment associated with diabetic preg-
nancies, particularly when obesity co-exists (Catalano 2011). Such
metabolic disruptions can affect organogenesis in early pregnancy,
and cardiac malformations in particular are more common in in-
fants of women with diabetes (Inkster 2006). As the pregnancy
progresses, this abnormal intrauterine environment may result in
the aforementioned neonatal morbidity, including being large-
for-gestational age; having neonatal hypoglycaemia, hyperbiliru-
binaemia, hypocalcaemia; and increased need for admission to an
intensive care unit (Macintosh 2006; Dunne 2009; Middleton
2016). It is becoming increasingly evident that exposure to ma-
ternal diabetes in utero may also have a longer-term negative im-
pact on the offspring, with one recent study noting that adolescent
offspring of women with Type 1 diabetes have lower cognitive
function compared with a control group even after adjusting for
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confounders (Bytoft 2016). In addition, long-term follow up of
offspring of women with diabetes reveal that they have elevated
rates of obesity and Type 2 diabetes later in life (Dabelea 2000).
Due to the association between hyperglycaemia and poor preg-
nancy outcomes, pregnant women with diabetes are advised to
keep blood glucose levels as close to normal as possible. Frequent
capillary blood-glucose monitoring and tight targets such as fast-
ing glucose of less than 5.3 mmol/L (96 mg/dL) and one-hour
post prandial of less than 7.8 mmol/L (140 mg/dL) are typically
recommended (NICE 2015).WhileHbA1c is not entirely reliable
in pregnancy, higher levels (HbA1c more than 6.0% to 6.5% or
more than 42 to 48 mmol/mol) may still be used as a marker of
poor glycaemic control and a higher risk pregnancy (Egan 2015;
Maresh 2015). In early pregnancy, there is increased insulin sen-
sitivity, lower glucose levels and lower insulin requirements in
women with Type 1 diabetes (ADA 2016). During the second
and early third trimesters, physiological insulin resistance increases
to facilitate the transfer of glucose across the placenta to the fe-
tus and ensure adequate growth and development (Farrar 2016).
This creates a significant challenge for women with diabetes who
must adjust their treatments regularly to match these increasing
insulin requirements and achieve their therapeutic goals. Typically,
care of these women involves significant input from a multidisci-
plinary team of specialists, with intensive monitoring throughout
the pregnancy, including frequent ultrasound surveillance of fetal
growth (NICE 2015). Unfortunately, the prevalence of large-for-
gestational age or macrosomia (or both) remains high in infants
of women with diabetes, even in pregnancies that are considered
’well-controlled’ (Evers 2002). In the past, some authors have pro-
posed to perform birth before full term in women with pre-exist-
ing diabetes, because of increased perinatal mortality during the
third trimester (Hunter 1989). This viewpoint is also reflected in
current clinical guidelines (NICE 2015).
Description of the intervention
A woman’s pregnancy is considered to be ’at term’ when her preg-
nancy duration reaches 37 weeks (Gulmezoglu 2012). Planned
birth involves the early birth of the infant either by induction
of labour or caesarean section. This typically takes place between
37 and 40 weeks’ gestation. Methods of induction vary accord-
ing to local protocols and typically depend on cervical status. The
process generally involves cervical ripening with misoprostol or
prostaglandin E2 (PGE2) followed by amniotomy and oxytocin
infusion if labour has not started (Boulvain 2016). An alterna-
tive is the expectant approach to the management of birth, which
refers to waiting for the spontaneous onset of labour in the absence
of any maternal or fetal issues that may necessitate birth (Bond
2017).
How the intervention might work
In pregnant women with pre-existing diabetes, the rationale for
performing an elective birth includes a possible reduction in peri-
natal morbidity and mortality, particularly in relation to compli-
cations associated with macrosomia (Brudenell 1989). Macroso-
mia is typically defined as a birthweight of more than 4000 g
(Feig 2015). It is associated with an increased chance of prolonged
labour, maternal trauma, emergency caesarean birth, and birth in-
juries for the infant, including clavicle fracture and brachial plexus
injury (Perlow 1996; Ju 2009). This has resulted in certain clini-
cal practice guidelines recommending that pregnant women with
diabetes be offered planned birth through induction of labour or
by elective caesarean section (if indicated) between 37 weeks plus
0 days, and 38 weeks plus 6 days, of pregnancy (NICE 2015).
A recent Cochrane review of induction of labour at or near term
for suspected fetal macrosomia (Boulvain 2016) concluded that
further trials are necessary to clarify if the benefits - including
lower mean birthweight and fewer instances of birth fracture and
shoulder dystocia - outweigh the risks, which include increased
perineal damage.
Why it is important to do this review
In 1989, the St Vincent declaration called on governments and
healthcare services to implement effective measures to achieve
pregnancy outcomes in women with diabetes that approximate
those of women without diabetes within five years (St Vincent
Declaration 1990). While this goal was not achieved, it is im-
portant that we strive to identify any measures that may assist in
meeting this target in our care for women with diabetes. Planned
birth may have potential benefits, possibly reducing the risks of
prolonged labour and elevated rates of caesarean section follow-
ing induction of labour (Macer 1992). Birth by caesarean sec-
tion, including elective caesarean, may increase the risk of mater-
nal morbidity including postpartum infections, haemorrhage or
uterine rupture during subsequent labour (Irion 1998). Induction
of labour may lead to increased interventions during labour and
birth and an increase in maternal morbidity (Khireddine 2013).
Furthermore, early-term birth is associated with an increased risk
ofmultiple neonatal morbidities including respiratory distress syn-
drome and the need for mechanical ventilation and admission to
a neonatal intensive care unit (ACOG 2013). Women’s views on
elective birth versus continued antenatal surveillance should also
be considered (Dodd 2014). The existing Cochrane review on
this topic, ’Elective delivery in diabetic pregnant women’(Boulvain
2001), does not make the distinction between women with estab-
lished, pre-existing diabetes and those with gestational diabetes
(a condition associated with carbohydrate intolerance resulting in
hyperglycaemia of variable severity with onset or first recognition
during pregnancy) (WHO 2014). Finally, this review was pub-
lished in 2001 and it is possible that additional evidence on this
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subject is now available for analysis.
Based on the above, it is now important to assess the effect of
planned birth compared with an expectant approach for pregnant
women with pre-existing diabetes on maternal and perinatal mor-
tality and morbidity. Women and healthcare professionals need
unbiased information on this subject and this is best provided by
meta-analysis of high-quality randomised controlled trials.
O B J E C T I V E S
To assess the effect of planned birth (either by induction of labour
or caesarean birth) at or near term gestation (37 to 40 weeks’
gestation) compared with an expectant approach, for improving
health outcomes for pregnant women with pre-existing diabetes
and their infants. The primary outcomes relate to maternal and
perinatal mortality and morbidity.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We planned to include all published randomised trials (including
those using a cluster-randomised design) and non-randomised tri-
als which compared planned birth at or near term gestation, with
an expectant approach for pregnant women with pre-existing di-
abetes. Non-randomised trials are trials in which participants are
allocated to treatment groups using non-random methods (e.g.
alternate) (EPOC 2016).
Cross-over studies were not eligible for inclusion as this design is
not appropriate for this intervention.
Studies published in abstract form only were eligible for inclusion
where information on risk of bias and primary or secondary out-
comes could be obtained.
Types of participants
Pregnant women, at or near term gestation (37 to 40 weeks’ gesta-
tion), with pre-existing diabetes (Type 1 or Type 2) as diagnosed
according to each included study.
Women with gestational diabetes are included in a different
Cochrane review, ’Planned birth at or near term for improving
health outcomes for pregnant women with gestational diabetes
and their infants’ (Biesty 2018)
We planned to exclude trials that included women both with ges-
tational diabetes and pre-existing diabetes, where data could not
be separated.
Types of interventions
Planned birth (induction of labour or caesarean section) at or near
term gestation (37 to 40 weeks’ gestation).
Induction of labour was defined by trial authors and may include
the use of prostaglandins, misoprostol, oxytocin, amniotomy or a
combination of these.
Comparisons
1. Planned birth (induction of labour/caesarean section), at or
near term gestation versus an expectant approach
An expectant approach to the management of birth refers to wait-
ing for the spontaneous onset of labour in the absence of any ma-
ternal of fetal issues that may necessitate birth (Bond 2017) (or
until 41 weeks’ gestation or more, when induction of labour may
be offered).
Types of outcome measures
For this review, we adapted the core outcome set agreed by con-
sensus between review authors of the Cochrane Pregnancy and
Childbirth systematic reviews for prevention and treatment of ges-
tational diabetes mellitus and pre-existing diabetes. The core out-
come set was adapted to ensure that the outcome measures in-
cluded were appropriate for this research question.
Primary outcomes
Maternal
1. Maternal mortality or serious maternal morbidity (e.g.
cardiac arrest, respiratory arrest, admission to intensive care unit
(ICU))
2. Caesarean section
3. Instrumental vaginal birth (forceps or vacuum)
Neonatal
1. Perinatal mortality rate (corrected, i.e. stillbirth and early
neonatal deaths excluding lethal congenital anomalies)
2. Shoulder dystocia
3. Large-for-gestational age (birthweight greater than the 90th
centile or as defined by the trial authors)
4. Acidaemia (as evident by a pH of less than 7.0 or a base
deficit greater than 12 mmol/L in umbilical arterial cord blood
or neonatal blood sample within the first hour of life, or both)
We planned to include all primary outcomes in a ’Summary of
findings’ table.
5Planned birth at or near term for improving health outcomes for pregnant women with pre-existing diabetes and their infants (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Secondary outcomes
Maternal
1. Maternal death
2. Cardiac arrest
3. Respiratory arrest
4. Admission to ICU
5. Intact perineum
6. Uterine rupture
7. Postpartum haemorrhage (defined as 1000 mL or more)
8. Postnatal depression (as measured by either the Edinburgh
Postnatal Depression Scale, the Postpartum Depression
Screening Scale, the Beck Depression Inventory or other
validated scales)
9. Maternal satisfaction (as measured by trial authors)
10. Intact perineum
Neonatal
1. Brachial plexus injury
2. Bone fracture at birth
3. Intracranial haemorrhage (all grades)
4. Hypoxic ischaemic encephalopathy
5. Respiratory distress syndrome
6. Neonatal hypoglycaemia (blood glucose concentrations
below the normal range, investigator defined)
7. Neonatal hyperbilirubinaemia (blood bilirubin
concentrations above the normal range, investigator defined)
8. Small-for-gestational age (birthweight below the third
centile or as defined by the trial authors)
9. Admission to neonatal ICU
10. Neurosensory disability (defined by a standardised
assessment tool at approximately two years of age)
Health service outcomes
1. Length of postnatal stay (mother)
2. Length of postnatal stay (baby)
3. Cost
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Register
by contacting their Information Specialist (15 August 2017).
The Register is a database containing over 24,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy andChildbirth’s Trials Regis-
ter, including the detailed search strategies for CENTRAL,MED-
LINE, Embase and CINAHL; the list of handsearched journals
and conference proceedings; and the list of journals reviewed via
the current awareness service, please follow this link to the edi-
torial information about the Cochrane Pregnancy and Childbirth
in the Cochrane Library and select the ’Specialized Register’ sec-
tion from the options on the left side of the screen.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Two people screen the search results and review the full text of
all relevant trial reports identified through the searching activities
described above. Based on the intervention described, each trial re-
port is assigned a number that corresponds to a specific Pregnancy
and Childbirth review topic (or topics), and is then added to the
Register. The Information Specialist searches the Register for each
review using this topic number rather than keywords. This results
in a more specific search set that has been fully accounted for in
the relevant review sections (Excluded studies; Studies awaiting
classification).
In addition, we searched ClinicalTrials.gov and the WHO Inter-
national Clinical Trials Registry Platform (ICTRP) for unpub-
lished, planned and ongoing trial reports using the searchmethods
detailed in Appendix 1.
Searching other resources
We searched the reference lists of retrieved studies. We did not
apply any language or date restrictions.
Data collection and analysis
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Selection of studies
Two review authors (LB, DD) independently assessed for inclu-
sion all potential eligible studies identified by our search strategy.
We planned to resolve any disagreement through discussion or, if
required, we planned to consult a third person.
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We created a study flow diagram tomap out the number of records
identified, included and excluded.
There were no studies identified as eligible for inclusion in this
review. In future updates, if there are any eligible studies identified
for inclusion, we will use the following methods.
Data extraction and management
We will design a form to extract data. For eligible studies, two re-
view authors will extract the data independently using the agreed
form. We will resolve discrepancies through discussion or, if re-
quired, we will consult a third person. We will pilot test the data
extraction tool on two papers prior to the conduct of the full re-
view and amend as necessary. One review author will enter all
data into Review Manager 5 (RevMan 2014) software which will
be checked for accuracy against the data extraction sheets by a
second review author. Where additional information is needed,
we will try to contact authors of the original reports to provide
further details. When information regarding any of the above is
unclear, we will attempt to contact authors of the original reports
to provide further details and will note this contact in the ’Char-
acteristics of included studies’ tables.
Assessment of risk of bias in included studies
Two review authors will independently assess risk of bias for each
study using the criteria outlined in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (Higgins 2011).Wewill resolve any
disagreement by discussion or by involving a third assessor. The
following sections refer to individually randomised trials. If clus-
ter-randomised trials are included we will use appropriate meth-
ods for assessing bias in these designs, as outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Where information on risk of bias relates to unpublished data or
correspondence with trialists, this will be noted in the ’Risk of bias’
table.
(1) Random sequence generation (checking for possible
selection bias)
We will describe for each included study the method used to gen-
erate the allocation sequence in sufficient detail to allow an assess-
ment of whether it should produce comparable groups.
We will assess the method as being at:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
• high risk of bias (any non-random process, e.g. alternate,
odd or even date of birth; hospital or clinic record number);
• unclear risk of bias (insufficient information to allow a
judgement).
(2) Allocation concealment (checking for possible selection
bias)
We will describe for each included study the method used to con-
ceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We will assess the methods as being at:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We will describe for each included study the methods used, if
any, to blind study participants and personnel from knowledge of
which intervention a participant received. We will consider that
studies are at low risk of bias if they were blinded, or if we judge
that the lack of blinding would be unlikely to affect results. We
will assess risk of detection bias for self-reported and objective
outcome measurement. We will assess the methods as being at:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We will describe for each included study the methods used, if any,
to blind outcome assessors from knowledge of which intervention
a participant received. We will consider blinding separately for
different outcomes where appropriate (for example, blinding may
have the potential to differently affect subjective versus objective
outcome measures).
We will assess methods used to blind outcome assessment as being
at low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We will describe for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We will state whether attrition and
exclusions were reported and the numbers included in the analysis
at each stage (compared with the total randomised women), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information is reported, or can be supplied by
the trial authors, we will re-include missing data in the analyses
which we undertake. We will assess risk of attrition bias for self-
reported and objective outcome measurement.
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We will assess methods as being at:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups, the proportion of missing
data were less than the effect size, i.e. unlikely to overturn the
results);
• high risk of bias (For self-reporting outcomes of maternal
depression and satisfaction we will judge attrition of > 20% as
high risk of bias. For other outcomes, we will explore if numbers
or reasons for missing data imbalance across groups; ‘as treated’
analysis done with substantial departure of intervention received
from that assigned at randomisation and judge based on these
findings);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We will describe for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
· We will assess the methods as being at:
• low risk of bias (where all of the study’s pre-specified
outcomes and all expected outcomes of interest to the review
have been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes have been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest are
reported incompletely and so cannot be used; study fails to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We will describe for each included study any important concerns
we have about other possible sources of bias.
We will assess whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We will make explicit judgements about whether studies are at
high risk of bias, according to the criteria given in the Handbook
(Higgins 2011). With reference to (1) to (6) above, we will assess
the likely magnitude and direction of the bias and whether we
consider it is likely to impact on the findings. We will explore the
impact of the level of bias through undertaking sensitivity analyses
- see Sensitivity analysis.
Assessment of the quality of the evidence using the
GRADE approach
We will assess the quality of the evidence using the GRADE ap-
proach as outlined in the GRADE handbook in order to assess the
quality of the body of evidence relating to the following outcomes
for the comparisons of planned birth (induction of labour or cae-
sarean section), at or near term gestation versus an expectation
approach.
1. Maternal mortality or serious maternal morbidity (e.g.
cardiac arrest, respiratory arrest, admission to ICU)
2. Caesarean section
3. Instrumental vaginal birth (forceps or vacuum)
4. Perinatal mortality rate (corrected, i.e. stillbirth and early
neonatal deaths excluding lethal congenital anomalies)
5. Shoulder dystocia
6. Large-for-gestational age (birthweight greater than the 90th
centile or as defined by the trial authors)
7. Acidaemia (as evident by a pH of less than 7.0 or a base
deficit greater than 12 mmol/L in umbilical arterial cord blood
or neonatal blood sample within the first hour of life, or both)
We will use the GRADEpro Guideline Development Tool to im-
port data fromReviewManager 5 (RevMan 2014) to create ’Sum-
mary of findings’ tables. A summary of the intervention effect and
a measure of quality for each of the above outcomes will be pro-
duced using the GRADE approach. The GRADE approach uses
five considerations (study limitations, consistency of effect, im-
precision, indirectness and publication bias) to assess the quality
of the body of evidence for each outcome. The evidence can be
downgraded from ’high quality’ by one level for serious limitations
(or by two levels for very serious limitations), depending on as-
sessments for risk of bias, indirectness of evidence, serious incon-
sistency, imprecision of effect estimates or potential publication
bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we will present results as summary risk
ratio with 95% confidence intervals.
Continuous data
For continuous data, we will use the mean difference if outcomes
are measured in the same way between trials. We will use the
standardised mean difference to combine trials that measure the
same outcome, but use different methods. We will report mean
and standardised mean differences with 95% confidence intervals.
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Unit of analysis issues
Cluster-randomised trials
Wewill include cluster-randomised trials in the analyses alongwith
individually randomised trials. We will adjust their sample sizes
using the methods described in the Cochrane Handbook for Sys-
tematic Reviews of Interventions (section 16.3.4 or 16.3.6) (Higgins
2011) using an estimate of the intracluster correlation co-efficient
(ICC) derived from the trial (if possible), from a similar trial or
from a study of a similar population. If we use ICCs from other
sources, we will report this and conduct sensitivity analyses to in-
vestigate the effect of variation in the ICC. If we identify both
cluster-randomised trials and individually-randomised trials, we
plan to synthesise the relevant information. We will consider it
reasonable to combine the results from both if there is little het-
erogeneity between the study designs and the interaction between
the effect of intervention and the choice of randomisation unit is
unlikely.
We will also acknowledge heterogeneity in the randomisation unit
and perform a sensitivity analysis to investigate the effects of the
randomisation unit.
Studies with multiple arms
For studies with multiple treatment arms, we will combine all
relevant experimental intervention groups in the study (e.g. groups
with differentmethods for induction of labour) into a single group
and all comparable relevant control intervention groups into a
single control group and perform a single pair-wise comparison,
as recommended in the Cochrane Handbook for Systematic Reviews
of Interventions (section 16.5.4) (Higgins 2011).
Dealing with missing data
For included studies, wewill note levels of attrition.Wewill explore
the impact of including studies with high levels of missing data
(more than 20%) in the overall assessment of treatment effect by
using sensitivity analysis.
For all outcomes, we will carry out analyses, as far as possible, on
an intention-to-treat basis, i.e. we will attempt to include all par-
ticipants randomised to each group in the analyses, and all partic-
ipants will be analysed in the group to which they were allocated,
regardless of whether they received the allocated intervention. The
denominator for each outcome in each trial will be the number
randomised minus any participants whose outcomes are known
to be missing.
Assessment of heterogeneity
We will assess statistical heterogeneity in each meta-analysis using
the Tau2, I2 and Chi2 statistics. We will regard inconsistency as
important if I2 is greater than 30% and either Tau2 is greater than
zero, or there is a low P value (less than 0.10) in the Chi2 test for
heterogeneity.
Assessment of reporting biases
If there are 10 or more studies in the meta-analysis we will in-
vestigate reporting biases (such as publication bias) using funnel
plots. We will assess funnel plot asymmetry visually. If asymmetry
is suggested by a visual assessment, we will perform exploratory
analyses to investigate it.
Data synthesis
We will carry out statistical analysis using Review Manager 5
(RevMan 2014). We will use fixed-effect meta-analysis for com-
bining data where it is reasonable to assume that studies are esti-
mating the same underlying treatment effect, i.e. where trials are
examining the same intervention, and the trials’ populations and
methods are judged to be sufficiently similar. If there is clinical
heterogeneity sufficient to expect that the underlying treatment
effects differ between trials, or if substantial statistical heterogene-
ity is detected, we will use random-effects meta-analysis to pro-
duce an overall summary if an average treatment effect across trials
is considered clinically meaningful. The random-effects summary
will be treated as the average of the range of possible treatment
effects and we will discuss the clinical implications of treatment
effects differing between trials. If the average treatment effect is
not clinically meaningful we will not combine trials.
If we use random-effects analyses, the results will be presented as
the average treatment effect with 95% confidence intervals, and
the estimates of Tau2 and I2.
Subgroup analysis and investigation of heterogeneity
If we identify substantial heterogeneity, we will investigate it us-
ing subgroup analyses and sensitivity analyses. We will consider
whether an overall summary is meaningful, and if it is, use ran-
dom-effects analysis to produce it.
We plan to carry out the following subgroup analyses.
1. Women with Type I diabetes versus women with Type 2
diabetes
2. Parity: primiparous women versus multiparous women
3. Birth by planned caesarean section versus planned elective
induction of labour
The following outcomes will be used in subgroup analysis.
Maternal
1. Maternal mortality or serious maternal morbidity (e.g.
cardiac arrest, respiratory arrest, admission to ICU)
2. Caesarean section
3. Instrumental vaginal birth (forceps or vacuum)
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Neonatal
1. Corrected perinatal mortality rate (stillbirths and early
neonatal deaths, excluding lethal congenital anomalies)
2. Shoulder dystocia
3. Large-for-gestational age (birthweight greater than the 90th
centile or as defined by the trial authors)
4. Acidaemia (as evident by a pH of less than 7.0 or a base
deficit greater than 12 mmol/L in umbilical arterial cord blood
or neonatal blood sample within the first hour of life, or both
Wewill assess subgroup differences using interaction tests available
within Review Manager 5 (RevMan 2014). We will report the
results of subgroup analyses quoting the Chi2 statistic and P value,
and the interaction test I2 value.
Sensitivity analysis
Wewill conduct a sensitivity analysis based on risk of bias in trials.
We will exclude all studies at high or unclear risk of bias for either
sequence generation or allocation concealment to see if this makes
any difference to the overall results. This is based on growing
empirical evidence that these factors are a particularly important
potential source of bias (Higgins 2011). We will limit sensitivity
analyses to primary outcomes.
R E S U L T S
Description of studies
No studies were eligible for inclusion in this review (see
Characteristics of excluded studies and Characteristics of studies
awaiting classification).
Results of the search
See: Figure 1.
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Figure 1. Study flow diagram.
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We identified 64 citations through our searches. After screening,
we retrieved 10 reports of six trials for potential inclusion in the
review.
Included studies
No studies were eligible for inclusion.
Excluded studies
We excluded five studies (Alberico 2017; Dhaneshwor 2011;
Ghosh 1979; Khojandi 1974; Worda 2017) (see Characteristics
of excluded studies). We excluded four studies ( Alberico 2017;
Dhaneshwor 2011; Khojandi 1974; Worda 2017) because the
participants were women with gestational diabetes. We excluded
the remaining study (Ghosh 1979) as no further details or pub-
lications have been made available in relation to this study since
the publication of the conference abstract 38 years ago.
We sent communications to the named contact author of one trial
(Henry 1992) to obtain data that related specifically to the women
with Type 1 or Type 2 diabetes in their trial. We are awaiting a
reply (See Characteristics of studies awaiting classification).
Risk of bias in included studies
As no studies were included in this review, we could not assess risk
of bias.
Allocation
No studies were included in this review, therefore we could not
assess the risk of selection bias.
Blinding
No studies were included in this review, therefore we could not
assess the risk of performance bias and detection bias.
Incomplete outcome data
No studies were included in this review, therefore we could not
assess the risk of attrition bias.
Selective reporting
No studies were included in this review, therefore we could not
assess the risk of reporting bias.
Other potential sources of bias
No studies were included in this review, therefore we could not
assess the risk of other potential sources of bias.
Effects of interventions
As there were no studies included in this review, we could not
assess the effects of interventions.
D I S C U S S I O N
We identified one completed trial (Henry 1992) which is awaiting
assessment. This trial was designed to compare elective induction
of labour with expectant management for reducing the incidence
of caesarean birth in pregnant women with insulin-requiring ges-
tational diabetes or pre-existing diabetes. However, to date, pub-
lished results do not separate the data of pregnant women with
pre-existing diabetes and women with gestational diabetes.
The risks for women with pre-existing diabetes and their neonates
during pregnancy have been explored in the earlier sections of
this review. The risks of having a baby diagnosed with macroso-
mia or large-for-gestational age (or both) remains high for these
women, even for those considered to have “well controlled dia-
betes” (Evers 2002). The association betweenmacrosomia and late
fetal death, and the potential for birth trauma, remain as concerns
(Dunne 2009). These concerns are reflected in clinical guidelines
(e.g. NICE 2015) which propose planned birth before term for
pregnant women with pre-existing diabetes. Yet, to date, no re-
sults from randomised trials have been published relating to the
effect of planned birth at or near term gestation, compared with an
expectant approach, for improving health outcomes for pregnant
women with pre-existing diabetes and their babies. This review
demonstrates the urgent need for such trials.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no evidence from randomised trials to inform implications
for practice. It is beyond the scope of this review to identify other
sources of evidence, as they have not been considered for inclusion.
Implications for research
This review demonstrates the urgent need for high-quality trials
evaluating the effectiveness of planned birth at or near term gesta-
tion for women with Type 1 or Type 2 diabetes, compared with an
12Planned birth at or near term for improving health outcomes for pregnant women with pre-existing diabetes and their infants (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
expectant approach. However, the equipoise on optimal approach
must be considered when planning such trials and attention must
be given to strategies to optimise the recruitment of women to
such studies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alberico 2017 This study explores immediate birth versus expectant management for women with gestational diabetes at term
Dhaneshwor 2011 This study compares expectant management versus induction of labour for women with gestational diabetes
Ghosh 1979 No further details or publication in the intervening period (38 years)
Khojandi 1974 The focus of this study was women with gestational diabetes.
Worda 2017 This study evaluates the impact of induction of labour on maternal and fetal outcomes in women with insulin-
dependent gestational diabetes
Characteristics of studies awaiting assessment [ordered by study ID]
Henry 1992
Methods Study Design: “randomised trial”
Duration of the study: 3.5 years
Participants Setting: Women’s Hospital, Los Angeles County- University of Southern California Medical Center
Inclusion criteria: “women diagnosed before pregnancy with insulin-dependent diabetes mellitus or non-insulin-
dependent diabetes mellitus without vascular complications or with gestational diabetes requiring insulin treatment
during pregnancy, and with good metabolic control of blood glucose levels ... 38 completed weeks gestation (266
days), good compliance with clinical appointments and home blood glucose monitoring, no abnormalities in the
twice weekly antepartum assessment with nonstress testing and amniotic fluid volume measurement performed from
34 weeks onward, singleton gestation and cephalic presentation, clinical and ultrasonographic estimation of fetal
weight <3800gm at 38 completed weeks with no evidence of intrauterine growth retardation, no other medical or
obstetric complications, a candidate for trial of vaginal delivery (no more than 2 previous C-sections)”
Interventions Planned birth:N = 100 women, “labour was induced with iv oxytocin .... in women with favourable Bishops Score
(<4), unscarred uteri and normal amniotic fluid indexes (>5.0cms), up to 3 applications of vaginal prostaglandin (3
mg) were used for cervical ripening before oxytocin treatment”
Expectant approach: N = 100 women, “expectant management consisted of daily split dose insulin therapy and
home blood glucose monitoring, weekly antenatal clinic visits, and twice-weekly antepartum testing”. Induction of
labour indicated by: “suspected fetal distress .... preeclampsia, maternal hyperglycaemia, estimated fetal weight >
4200gm, 42 weeks gestation”
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Henry 1992 (Continued)
Outcomes Outcomes considered relevant to this review: mode of delivery - vaginal delivery, caesarean delivery; infant birth-
weight - macrosomia, large-for-gestational age; infant outcome - shoulder dystocia, birth trauma (bone fracture, Erbs
palsy), hypoglycaemia, mortality
Notes Funding: not known
Trial authors declaration of Interest: none declared
The authors were contacted on: 10th Jan 2017, to obtain data specifically related to pregnant women with pre-
existing diabetes in both the experimental and control groups
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Search terms for ICTRP and ClinicalTrials.gov
WHO International Clinical Trials Registry Platform (ICTRP)
(we ran each line and alternative spelling separately and then de-duplicated)
GDM AND c(a)esarean
diabetes AND c(a)esarean
diabetic AND c(a)esarean
planned AND birth AND GDM
planned AND birth AND diabetes
planned AND birth AND diabetic
elective AND birth AND GDM
elective AND birth AND diabetes
elective AND birth AND diabetic
induction AND labo(u)r AND diabetes
induction AND labo(u)r AND GDM
Induction AND labo(u)r AND diabetic
expectant AND birth AND GDM
expectant AND birth AND diabetic
expectant AND birth AND diabetes
ClinicalTrials.gov
(we ran each search separately and then de-duplicated)
Advanced search
1.
diabetes OR diabetic OR GDM - Condition
cesarean OR caesarean - Intervention
2.
diabetic OR diabetes OR GDM - Condition
(planned OR elective OR expectant) AND (birth OR delivery) - Intervention
3.
diabetes OR diabetic OR GDM - Condition
induction AND (labour OR labor)
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childbirth systematic reviews to support clinical guidelines, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The title has changed from ’Planned elective birth at or near term for improving health outcomes for pregnant women with pre-
gestational diabetes (Type 1 or Type 2)’ to ’Planned birth at or near term for improving health outcomes for pregnant women with
pre-existing diabetes and their infants’.
The protocol for this Cochrane review was published in PROSPERO on 26 September 2017 - see http://www.crd.york.ac.uk/
PROSPERO/display record.asp?ID=CRD42017072506. The protocol was not published in the Cochrane Library.
N O T E S
The original review ’Elective delivery in diabetic pregnant women’ (Boulvain 2001) has now been split into two reviews.
• Planned birth at or near term for improving health outcomes for pregnant women with gestational diabetes and their infants
(Biesty 2018).
• Planned birth at or near term for improving health outcomes for pregnant women with pre-existing diabetes and their infants
(this review).
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